FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912141315> ?p ?o ?g. }

• W2912141315 endingPage "301" @default.
• W2912141315 startingPage "294" @default.
• W2912141315 abstract "Endorectal brachytherapy is an attractive option in the neoadjuvant setting for locally advanced rectal cancer, but it is not considered standard of care.This study aimed to compare pathologic outcomes of patients with clinical T3 rectal cancer who underwent high-dose-rate endorectal brachytherapy with those who underwent conventional external beam radiotherapy.This study is a retrospective chart review.This study was conducted in a single large tertiary academic colorectal surgery practice in Canada.Adult patients with MRI-staged T3 rectal adenocarcinoma treated with neoadjuvant radiotherapy followed by total mesorectal excision from 2007 to 2016 were included.Neoadjuvant radiotherapy was delivered by high-dose-rate endorectal brachytherapy or conventional external beam radiotherapy.Primary outcome was pathologic complete response, defined as ypT0N0. Secondary outcomes included tumor (T stage) and lymph node (N stage) downstaging and tumor regression grade.Ninety-nine patients were identified as having clinical T3 rectal cancer based on blinded pretreatment MRI review. Mean age was 66.2 years (± 6.2) and 59 patients (59.6%) were male. Thirty-three patients were clinically node negative (33.3%), 45 had c-N1 disease (45.5%), and 21 had c-N2 disease (21.2%). Sixty-four patients (64.6%) underwent high-dose-rate endorectal brachytherapy and 35 (35.4%) underwent external beam radiotherapy. The high-dose-rate endorectal brachytherapy group had a lower median mesorectal depth of invasion (4 mm vs 5 mm, p = 0.010); all other preoperative tumor characteristics were similar in both groups. Eighteen patients (18.2%) achieved pathologic complete response: 12 in the high-dose-rate endorectal brachytherapy group and 6 in the conventional external beam radiotherapy group (18.8% vs 17.1%, p = 0.84). High-dose-rate endorectal brachytherapy was superior to conventional radiotherapy for tumor (T stage) downstaging (59.4% vs 28.6%, p = 0.0030) but not for lymph node (N stage) downstaging (35.9% vs 51.4%, p = 0.14).This study was limited by its retrospective nature and modest sample size.Neoadjuvant treatment of T3 rectal cancer with high-dose-rate endorectal brachytherapy appears to achieve equivalent rates of pathologic complete response and superior T-stage downstaging compared with conventional external beam radiotherapy. See Video Abstract at http://links.lww.com/DCR/A905." @default.
• W2912141315 created "2019-02-21" @default.
• W2912141315 creator A5010297386 @default.
• W2912141315 creator A5010884753 @default.
• W2912141315 creator A5021647048 @default.
• W2912141315 creator A5025556615 @default.
• W2912141315 creator A5030976762 @default.
• W2912141315 creator A5031019159 @default.
• W2912141315 creator A5040191228 @default.
• W2912141315 creator A5046302296 @default.
• W2912141315 creator A5059883636 @default.
• W2912141315 date "2019-03-01" @default.
• W2912141315 modified "2023-09-30" @default.
• W2912141315 title "Is the Pathologic Response of T3 Rectal Cancer to High-Dose-Rate Endorectal Brachytherapy Comparable to External Beam Radiotherapy?" @default.
• W2912141315 cites W134304227 @default.
• W2912141315 cites W146593897 @default.
• W2912141315 cites W1585172067 @default.
• W2912141315 cites W1917005948 @default.
• W2912141315 cites W1970244461 @default.
• W2912141315 cites W1988071481 @default.
• W2912141315 cites W1988577462 @default.
• W2912141315 cites W1991897088 @default.
• W2912141315 cites W1999983150 @default.
• W2912141315 cites W2002157633 @default.
• W2912141315 cites W2026559728 @default.
• W2912141315 cites W2077990157 @default.
• W2912141315 cites W2099027798 @default.
• W2912141315 cites W2099119383 @default.
• W2912141315 cites W2105963543 @default.
• W2912141315 cites W2106014206 @default.
• W2912141315 cites W2107371365 @default.
• W2912141315 cites W2109868752 @default.
• W2912141315 cites W2113353705 @default.
• W2912141315 cites W2125452425 @default.
• W2912141315 cites W2127699440 @default.
• W2912141315 cites W2142541082 @default.
• W2912141315 cites W2144717403 @default.
• W2912141315 cites W2152883689 @default.
• W2912141315 cites W2154336963 @default.
• W2912141315 cites W2171810236 @default.
• W2912141315 doi "https://doi.org/10.1097/dcr.0000000000001220" @default.
• W2912141315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30741768" @default.
• W2912141315 hasPublicationYear "2019" @default.
• W2912141315 type Work @default.
• W2912141315 sameAs 2912141315 @default.
• W2912141315 citedByCount "5" @default.
• W2912141315 countsByYear W29121413152019 @default.
• W2912141315 countsByYear W29121413152022 @default.
• W2912141315 countsByYear W29121413152023 @default.
• W2912141315 crossrefType "journal-article" @default.
• W2912141315 hasAuthorship W2912141315A5010297386 @default.
• W2912141315 hasAuthorship W2912141315A5010884753 @default.
• W2912141315 hasAuthorship W2912141315A5021647048 @default.
• W2912141315 hasAuthorship W2912141315A5025556615 @default.
• W2912141315 hasAuthorship W2912141315A5030976762 @default.
• W2912141315 hasAuthorship W2912141315A5031019159 @default.
• W2912141315 hasAuthorship W2912141315A5040191228 @default.
• W2912141315 hasAuthorship W2912141315A5046302296 @default.
• W2912141315 hasAuthorship W2912141315A5059883636 @default.
• W2912141315 hasConcept C121608353 @default.
• W2912141315 hasConcept C126322002 @default.
• W2912141315 hasConcept C126838900 @default.
• W2912141315 hasConcept C146357865 @default.
• W2912141315 hasConcept C151730666 @default.
• W2912141315 hasConcept C2775908122 @default.
• W2912141315 hasConcept C2777201421 @default.
• W2912141315 hasConcept C2777416452 @default.
• W2912141315 hasConcept C2780849966 @default.
• W2912141315 hasConcept C509974204 @default.
• W2912141315 hasConcept C526805850 @default.
• W2912141315 hasConcept C71924100 @default.
• W2912141315 hasConcept C86803240 @default.
• W2912141315 hasConceptScore W2912141315C121608353 @default.
• W2912141315 hasConceptScore W2912141315C126322002 @default.
• W2912141315 hasConceptScore W2912141315C126838900 @default.
• W2912141315 hasConceptScore W2912141315C146357865 @default.
• W2912141315 hasConceptScore W2912141315C151730666 @default.
• W2912141315 hasConceptScore W2912141315C2775908122 @default.
• W2912141315 hasConceptScore W2912141315C2777201421 @default.
• W2912141315 hasConceptScore W2912141315C2777416452 @default.
• W2912141315 hasConceptScore W2912141315C2780849966 @default.
• W2912141315 hasConceptScore W2912141315C509974204 @default.
• W2912141315 hasConceptScore W2912141315C526805850 @default.
• W2912141315 hasConceptScore W2912141315C71924100 @default.
• W2912141315 hasConceptScore W2912141315C86803240 @default.
• W2912141315 hasIssue "3" @default.
• W2912141315 hasLocation W29121413151 @default.
• W2912141315 hasLocation W29121413152 @default.
• W2912141315 hasOpenAccess W2912141315 @default.
• W2912141315 hasPrimaryLocation W29121413151 @default.
• W2912141315 hasRelatedWork W1966944530 @default.
• W2912141315 hasRelatedWork W2010917826 @default.
• W2912141315 hasRelatedWork W2043597413 @default.
• W2912141315 hasRelatedWork W2043764901 @default.
• W2912141315 hasRelatedWork W2055348823 @default.
• W2912141315 hasRelatedWork W2788839829 @default.
• W2912141315 hasRelatedWork W2966036943 @default.
• W2912141315 hasRelatedWork W3029213237 @default.

• next